Immunocore is a privately-owned, clinical-stage, biotechnology company, developing novel drugs to treat cancer and viral disease. The first product candidate from its world leading T Cell Receptor technology platform, IMCgp100, entered clinical trials in melanoma in 2010. Read more»
Our Technology in action
T Cell Receptors naturally recognise diseased cells. Immunocore’s competitive advantage is its ability to engineer high affinity T Cell Receptors and link them to an antibody fragment, anti-CD3, which can activate the immune system to kill the targeted cancer or viral cells. These bifunctional molecules, called ImmTACS, have the potential to be very potent anti-cancer or anti-viral agents. Watch the technology in action in a video.